Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
Pharmatimes has reported several new products coming to market this month:
In the UK Alimta (pemetrexed) developed by Eli Lilly has been cleared for sale by the National Institute for Health and Clinical Excellence (NICE). It will be used to treat malignant pleural mesothelioma a type of aggressive lung cancer associated with asbestos exposure in cases where the patient cannot be operated on.
In Europe the European Medicines Agency (EMA) has given Roche permission for ‘significantly wider use’ of Avastin (bevacizumab) for metastatic colorectal cancer allowing Avastin to be used in combination with any chemotherapy drug for first and later-line treatment. Roche has also won expanded approval for its oral oncology drug Xeloda (capecitabine) for advanced colorectal cancer. http://www.ecancermedicalscience.com/news-insider-news.asp?itemId=94
In Japan Bayer received approval for use of Nexavar (sorafenib) to treat advanced renal cell carcinoma (kidney cancer) as well as gaining priority review status with the Ministry of Health Labour and Welfare (MHLW) for its use against liver cancer.
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.